ORPHA:570438
HHV-8-associated multicentric Castleman disease
Also known as: Human herpesvirus-8-associated multicentric Castleman disease
Publications
1,900
Trials
8
Interventional, condition-specific
Researchers
1,143
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019754
- UMLS:C1334815
- NCIT:C27855
Additional Mondo synonyms (3)
MCD · multicentric Angiofollicular lymphoid hyperplasia · multicentric Castleman's disease
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,900 matched papers (471 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
8 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
1,900
1,900 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
1,900 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
471 in the last 10 years · low confidence
Phrase hits: 1,900 · MeSH hits: 0
Who's working on it?
1,143
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Fajgenbaum DC5 papers · 2025
Orphan Disease Center, Perelman School of Medicine, University of Pennsylvania, Translational Research Laboratory, Philadelphia, PA, USA; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: davidfa@mail.med.upenn.edu.
Papers in Europe PMC - 02Boutboul D4 papers · 2026
Clinical Immunopathology Department, St Louis Hospital, AP-HP, University of Paris, INSERM U967 HIPI, Paris, France.
Papers in Europe PMC - 03Kawakami A4 papers · 2025
a Unit of Advanced Preventive Medical Sciences , Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan.
Papers in Europe PMC - 04Koga T4 papers · 2025
a Unit of Advanced Preventive Medical Sciences , Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan.
Papers in Europe PMC - 05Sumiyoshi R4 papers · 2025
a Unit of Advanced Preventive Medical Sciences , Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan.
Papers in Europe PMC - 06Akiyama M3 papers · 2026
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan.
Papers in Europe PMC - 07Chen X3 papers · 2025
Department of Hernia and Colorectal Surgery, The Second Hospital of Dalian Medical University, Dalian, People's Republic of China.
Papers in Europe PMC - 08Fukui S3 papers · 2025
Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, JPN.
Papers in Europe PMC - 09Galicier L3 papers · 2026
Department of Clinical Immunology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
Papers in Europe PMC - 10Kaneko Y3 papers · 2026
Department of Radiology, Gifu University Hospital, 1-1 Yanagido, Gifu City 501-1194, Japan.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
8
interventional trials for this specific condition
8 interventional trials matched this specific condition name; none in our sample are currently recruiting. 14 trials are registered for Castleman disease, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
8 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 90.6th percentile).
low confidence · 90.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
8 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: Castleman disease
14
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07085039·RECRUITING·Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
Conditions: Castleman's Disease (CD) · Idiopathic Multicentric Castleman's Disease·Matched via name phrase
- NCT06052618·RECRUITING·Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
Conditions: KSHV Inflammatory Cytokine Syndrome (KICS) · Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease·Matched via name phrase
- NCT05907759·RECRUITING·Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Conditions: Lymphoma, Primary Effusion·Matched via name phrase
- NCT06643091·NOT YET RECRUITING·Nintedanib Treatment in Unicentric Castleman Disease
Conditions: Castleman Disease·Matched via name phrase
Observational and natural-history studies
3 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT00006518·RECRUITING·Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
Conditions: HIV · Kaposi's Sarcoma · Lymphomas · Multicentric Castleman's Disease·Matched via name phrase
- NCT04968288·RECRUITING·Natural History of KSHV-Associated Multicentric Castleman s Disease
Conditions: Multicentric Castleman s Disease·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"HHV-8-associated multicentric Castleman disease" OR "Human herpesvirus-8-associated multicentric Castleman disease" OR "multicentric Angiofollicular lymphoid hyperplasia" OR "multicentric Castleman's disease"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"HHV-8-associated multicentric Castleman disease" OR "Human herpesvirus-8-associated multicentric Castleman disease" OR "multicentric Angiofollicular lymphoid hyperplasia" OR "multicentric Castleman's disease"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 8 interventional · 3 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"Castleman disease"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: MCD
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (1900) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T18:31:44.137Z
